GlassScriptPhysician profile
Joseph G Bolin
NPI 1851477210
$2,313.58
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $128 · 2021: $769 · 2022: $640 · 2023: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445 · Education: $52.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.85 |
| Education | $52.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.37 | 2021-2023 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $237.45 | 2019-2023 | Breztri, Farxiga |
| Lilly USA, LLC | $223.95 | 2021-2023 | Mounjaro, Trulicity, Emgality |
| Amgen INC. | $218.23 | 2019-2023 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $206.26 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $162.99 | 2019-2023 | Wegovy |
| Biohaven Pharmaceuticals, INC. | $140.28 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $107.72 | 2022 | |
| Sanofi-Aventis U.S. LLC | $100.48 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $66.99 | 2019 | |
| Pfizer INC. | $58.81 | 2019-2023 | |
| Pharming Healthcare, INC. | $52.00 | 2023 | |
| Abbott Laboratories | $37.16 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.59 | 2021 | |
| Exact Sciences Corporation | $24.83 | 2023 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $19.34 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.32 | 2023 | Quviviq |
| Corium, LLC | $17.21 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $16.84 | 2023 | Auvelity |
| Eisai INC. | $13.92 | 2021 | |
| Boston Scientific Corporation | $13.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.34 | 2019 | |
| Allergan, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.